Voices of Biotech
Podcast: MilliporeSigma says education vital to creating unbreakable chain for sustainability
MilliporeSigma discusses the importance of people, education, and the benefits of embracing discomfort to bolster sustainability efforts.
- Sponsored Content
- Manufacturing
Development of an Automated AAV8 Capsid Titer Assay on Gyrolab® xPand Immunoassay Platform
BPI Contributor
December 10, 2021
20 Min View
Date: Dec 10, 2021
Duration: 20 Min
Sponsored by Gyros
This webcast features: Matthew Lotti, Senior Research Associate, Ultragenyx.
The fast-growing gene therapy industry is in pressing need for fast and reliable analytical methods to accelerate bioprocess development and manufacturing of AAV viral vectors.
Matt Lotti, Senior Research Associate II at Ultragenyx, a pharmaceutical company developing therapies for patients with rare genetic diseases, will present how the Analytical Development team at Ultragenyx developed a Gyrolab-based assay that demonstrates acceptable accuracy and precision for supporting in-process testing of AAV8 capsid titer.
The automation-based capsid titer assay enabled the reduction of costs and materials, provided improved assay throughput, and expanded the assay dynamic range.
Learning Objectives:
Insight on the needs in AAV development, manufacturing and analytics.
Accurate determination of AAV capsid titer in process intermediate samples that are low in concentration and/or high in impurities levels.
Learn how automated analytical solutions, such as the Gyrolab platform can boost throughput in analytical labs with faster, more accurate, and more reproducible assay results.
Just fill out the form below to watch the recorded webcast now.
About the Author(s)
You May Also Like
Upcoming Webcasts
Jun 17 - Jun 20, 2024
Jun 17 - Jun 20, 2024
Our Biopharmaceutical School is the perfect course to gain a well-rounded understanding of the Biopharmaceutical industry. Over three days, you will understand the principle steps in the biopharmaceutical lifecycle, including: raw material selection, up and downstream processes and core technology. Additionally, you will be familiarised with the latest industry trends, including Industry 4.0, and how these are likely to impact the industry’s evolution.
Through a combination of sessions led by experts from the likes of GSK and Pall Biotech, as well as group discussions with your peers, you will learn how to bring a biopharmaceutical drug to market. Each day will be chaired by a different member of the BioProcess International Academy faculty and there will also be time for networking and Q&As with the experts.
Learn More